ACTR-09. CLINICAL RESULTS OF THE EORTC RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1ST RECURRENCE OF GRADE II OR III GLIOMA WITHOUT 1p/19q CO-DELETION | Zendy

AI Assistant Blog Pricing

ACTR-09. CLINICAL RESULTS OF THE EORTC RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1ST RECURRENCE OF GRADE II OR III GLIOMA WITHOUT 1p/19q CO-DELETION

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.